The role of fosinopril in the treatment and prevention of cardiovascular diseases
https://doi.org/10.21518/2079-701X-2015-12-28-33
Abstract
In Russia, cardiovascular diseases account for 57% of deaths in the overall mortality. Arterial hypertension (AH) is one of the main risk factors (RF) for cardiovascular diseases (along with dyslipidemia, smoking, metabolic syndrome, diabetes mellitus, alcohol abuse, etc.). AH is the largest contributor to cardiovascular morbidity and mortality, and a very common disease in Russia (about 40% of the adult Russian population suffer from hypertension).
About the Author
G. A. Baryshnikova
Central State Medical Academy of the Presidential Administration of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Guthrie R. FosinopriL: an overview. Am J Cardiol., 1993, 72: 22H-24H.
2. Sugarman AA, Couchman T et aL, Advanced age per se no influence on the pharmacokinetics of the active diacid of fosinopriL. J Clin Pharmacol, 1986, 26:541-560.
3. Vetter W. Treatment of senile hypertension: the FosinopriL in OLd Patients Study (FOPS). Am J Hypertens, 1997,10(10 Pt 2): 255S-261S.
4. Berdah J, Guest M, SaLvador M. Study of the efficacy and safety of fosinopriL in generaL practice in 19,435 hypertensive patients (FLIGHT Study). Ann CardiolAngeiol, 1998, 47(3): 169-75.
5. Leonetti G, Trimarco B, CoLLatina S et aL. An effective approach for treating eLderLy patients with isoLated systoLic hypertension: resuLts of an ItaLian muLticenter study with fosinopriL. Am J Hypertens, 1997, 10(10 Pt 2): 230-235.
6. Tatti P, Pahor M, Byington RP et aL. Outcome resuLts of the fosincpriL vs amLodipine cardiovascuLar events randomized triaL (FACET) in patients with hypertension and NIDDM. Diabetes Care, 1998, 21: 597-603.
7. Fernandez M, Madero R, GonzaLez D et aL. Combined versus singLe effect of fosinopriL and hydrochLorothiazide in hypertensive patients. Hypertension, 1994, 23(1): I207-10.
8. BiLge AK, AtiLgan D, Tukek T et aL. Effects of amLodipine and fosinopriL on heart rate variabiLity and Left ventricuLar mass in miLd-to-moderate essentiaL hypertension. Int J Clin Pract, 2005, 59(3): 306-10.
9. Kirpizidis HG, Papazachariou GS. Comparative effects of fosinopriL and nifedipine on regression of Left ventricuLar hypertrophy in hypertensive patients: a doubLe-bLind study. Cardiovasc Drugs Ther, 1995, 9(1): 141-3.
10. HoLdaway IM, GambLe GD, Sanders GA et aL. Effect of fosinopriL on cardiac and metaboLic parameters in patients with NIDDM. Diabetes Care, 1994, 17(12): 1476-9.
11. Sarnak MJ, Levey AS, SchooLwerth AC et aL. Kidney disease as a risk factor for deveLopment of cardiovascuLar disease: a statement from the American Heart Association CounciLs on Kidney in CardiovascuLar Disease, High BLood Pressure Research, CLinicaL CardioLogy, and EpidemioLogy and Prevention. Circulation, 2003, 108: 2154-69.
12. Мухин Н.А., Моисеев B.C., Кобалава Ж.Д. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер. Архив, 2004, 6: 39-46.
13. Моисеев B.C., Кобалава ЖД. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин. Фармак. тер., 2002, 11(3): 16-18.
14. Ronco C, House AA, Haapio M. CardiorenaL syndrome: refining the definition of a compLex symbiosis gone wrong. C. Ronco, Intensive Care Med., 2008, 34: 957-962.
15. Терещенко С.Н., Жиров И.В. Место ингибиторов ангиотензинпревращающего фермента в лечении кардиоренального синдрома. Эффективная фармакотерапия. 2011, 2.
16. Smith GL, Lichtman JH, Bracken MB, ShLipak MG, PhiLLips CO, DiCapua P et aL. RenaL impairment and outcomes in heart faiLure: Systematic review and meta-anaLysis J. Am. Coll. Cardiol., 2006, 47: 987-96.
17. Zou AP, Li N, CowLey AW. Jr. Production and actions of superoxide in the renaL meduLLa. Hypertension, 2001, 37: 547-53.
18. Greenbaum R, ZuccheLLi P, Caspi A et aL. Comparison of the pharmacokinetics of fosino-priLat with enaLapriLat and LisinopriL in patients with congestive heart faiLure and chronic renaL insufficiency. Br J Clin Pharmacol, 2000, 49(1): 23-31.
19. Fogari R, Preti P, Zoppi A. Effects of amLodipine fosinopriL combination on microaLbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens, 2002, 15(12): 1042-9.
20. Marin R, RuiLope LM, ALjama P et aL. A random comparison of fosinopriL and nifedipine GITS in patients with primary renaL disease. J Hypertens, 2001, 19(10): 1871-6.
21. AsseLbergs FW, Diercks GF, HiLLege HL et aL. Prevention of RenaL and VascuLar Endstage Disease Intervention TriaL (PREVEND IT) Investigators. Effects of fosinopriL and pravas-tatin on cardiovascuLar events in subjects with microaLbuminuria. Circulation, 2004, 110(18): 2809-16.
22. HiLLege HL, Girbes AR, de Kam PJ et aL. Renal function, neurohormonaL activation, and survivaL in patients with chronic heart faiLure. Circulation, 2000, 102: 203-10.
23. CareLLa MJ, Gossain VV, Jones J. The effects of a Low-dose regimen of fosinopriL on eLevated urinary aLbumin excretion in normotensive type 1 diabetic patients. J Med, 1999, 30(5-6): 305-20.
24. Erhardt L, MacLean A, I Lgenfritz J et aL. FosinopriL attenuates cLinicaL deterioration and improves exercise toLerance in patients with heart faiLure. FosinopriL Efficacy/Safety TriaL (FEST) Study Group. Eur Heart J, 1995, 16(12): 1892-9.
25. GaLatius-Jensen S, WrobLewski H, EmmeLuth C et aL. PLasma endotheLin in congestive heart faiLure: effect of the ACE inhibitor, fosinopriL. Cardiovasc Res, 1996, 32(6): 1148-54.
26. Мареев В.Ю. Фармакоэкономическая оценка использования ингибитора АПФ в амбулаторном лечении больных с сердечной недостаточностью (ФАСОН). Сердечная Недостаточность, 2002, 3(1): 38-39.
27. Borghi C et aL. Post acute myocardiaL infarction. The fosinopriL in acute myocardiaL infarction study (FAMIS). Am J Hypertens, 1997, 10: 247-54.
28. Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ, ФАСОН, ФАГОТ). Сердечная недостаточность, 2003, 4(5): 261-264.
29. Карпов Ю.А. Фозиноприл при лечении артериальной гипертонии (ФЛАГ): российская программа оценки практической достижимости целевых уровней артериального давления. РМЖ, 2001, 9(10): 406-10.
30. Чазова И.Е. Первые результаты исследования ФАГОТ. Consihum medicum, 2002, 4(11): 596-98.
31. Sharif MN, Evans BL, PyLypchuk GB. Cough induced by quinapriL with resoLution after changing to fosinopriL. Ann Pharmacotherapy, 1994, 28: 720-2.
32. David D, JaLLad N, Germino FW et aL. A comparison of the cough profiLe of fosinopriL and enaL-apriL in hypertensive patients with a history of ACE-inhibitor-associated cough. Am J Ther, 1995, 2 (10): 806-1317.
Review
For citations:
Baryshnikova GA. The role of fosinopril in the treatment and prevention of cardiovascular diseases. Meditsinskiy sovet = Medical Council. 2015;(12):28-33. (In Russ.) https://doi.org/10.21518/2079-701X-2015-12-28-33
Views:
445
Email this article 